Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units

Epidemiological Features of Emergent Highly Resistant Bacteria in Tunisian Intensive Care Units: A Prospective Multicenter National Observational Study (NOSOREA-3)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06392568

Acronym

NOSOREA3

Enrollment

500

Registered

2024-04-30

Start date

2024-04-01

Completion date

2024-05-31

Last updated

2024-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carbapenem Resistant Bacterial Infection, Critical Illness, Cross Infection, Vancomycin-Resistant Enterococcal Infection

Keywords

Critical care, Healthcare Associated Infections, Drug resistance

Brief summary

Investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and glycopeptides-resistant enterococcus.

Detailed description

In 2022, a previous one-day point-prevalence multicenter study (NOSOREA2, NCT05547646) showed that most prevalent pathogens causing healthcare-associated infections were carbapenem resistant enterobacteriaceae. In 2017, (NOSOREA1, LA TUNISIE MEDICALE - 2018 ; Vol 96 (10/11)), most prevalent pathogens were non-fermenting pathogens. Faced with this major epidemiological change within Tunisian ICUs, we decided to launch a 3rd survey under the aegis of the 'Association tunisienne de réanimation'. We aimed to investigate the epidemiology, risk factors and impact on clinical practice of healthcare-associated infections with emergent highly drug-resistant (eHDR) pathogens, particularly carbapenem resistant enterobacteriaceae and glycopeptides-resistant enterococcus. So we conducted a multicenter prospective collection that will take place over 2 months.

Interventions

OTHERepidemiological records

Healthcare associated infections due to emergent highly resistant bacteria, sites, risk factors, treatment and outcome

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult ICU patients admitted during the study period

Exclusion criteria

* none

Design outcomes

Primary

Measure	Time frame	Description
Highly resistant bacterial healthcare associated infections	2 months	Incidence of eHRB healthcare associated infections in ICU
Epidemiological features of Highly resistant bacterial healthcare associated infections healthcare associated infections in ICU	2 months	Causative micro-organisms, sites and risk factors of eHRB healthcare associated infections in ICU

Countries

Tunisia

Contacts

Primary ContactAmira JAMOUSSI, Professor

amira.jamoussi@fmt.utm.tn+21698375250

Backup ContactJalila BEN KHELIL, Professor

jalila.benkhelil@fmt.utm.tn+21653689799

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026